Table A9.
Pulmonary related adverse events in Study 1.
| Placebo (n = 36) |
OnabotA 240 U (n = 36) |
OnabotA 360 U (n = 36) |
|
|---|---|---|---|
| Overall | 11 (30.6%) | 8 (22.9%) | 16 (43.2%) |
| Nasopharyngitis | 2 (5.6%) | 3 (8.6%) | 6 (16.2%) |
| Bronchitis | 0 (0.0%) | 1 (2.9%) | 2 (5.4%) |
| Upper respiratory tract infection | 2 (5.6%) | 0 (0.0%) | 2 (5.4%) |
| Oropharyngeal pain | 0 (0.0%) | 2 (5.7%) | 1 (2.7%) |
| Cough | 1 (2.8%) | 1 (2.9%) | 1 (2.7%) |
| Pneumonia | 1 (2.8%) | 0 (0.0%) | 1 (2.7%) |
| COPD | 0 (0.0%) | 0 (0.0%) | 1 (2.7%) |
| Nasal congestion | 0 (0.0%) | 0 (0.0%) | 1 (2.7%) |
| Pleurisy | 0 (0.0%) | 0 (0.0%) | 1 (2.7%) |
| Asthma | 0 (0.0%) | 1 (2.9%) | 0 (0.0%) |
| Rhinitis | 0 (0.0%) | 1 (2.9%) | 0 (0.0%) |
| Influenza | 1 (2.8%) | 0 (0.0%) | 0 (0.0%) |
| Laryngitis | 1 (2.8%) | 0 (0.0%) | 0 (0.0%) |
| Musculoskeletal chest pain | 1 (2.8%) | 0 (0.0%) | 0 (0.0%) |
| Pharyngitis | 1 (2.8%) | 0 (0.0%) | 0 (0.0%) |
| Sinus congestion | 1 (2.8%) | 0 (0.0%) | 0 (0.0%) |
| Sinusitis | 1 (2.8%) | 0 (0.0%) | 0 (0.0%) |
| Wheezing | 1 (2.8%) | 0 (0.0%) | 0 (0.0%) |
COPD = chronic obstructive pulmonary disease.